Objective

2

To observe the clinical efficacy of Jiangshi Xuantong decoction （JSXT） in the treatment of peripheral neuropathy patients with arthralgia syndrome caused by wind， heat， and dampness，investigate the changes in common clinical evaluation indexes and electrophysiology，and verify its effectiveness and safety.

Method

2

A total of 120 patients were randomly divided into a JSXT group （

n

=60） and a mecobalamin group （

n

=60）. The changes in Toronto clinical neuropathy scores （TCNSs），traditional Chinese medicine （TCM） syndrome scores，efficacy for TCM syndrome，electrophysiological results in the electromyogram， and safety indexes before and after JSXT treatment of peripheral neuropathy were observed to determine the clinical efficacy and safety of JSXT for peripheral neuropathy.

Result

2

No significant differences in various indexes among patients were observed before treatment. The TCM syndrome score，TCNS， and electrophysiological results in the electromyogram of the patients after treatment were significantly higher than those before treatment （

P

<

0.05）. The evaluation indexes of the treatment group were significantly higher than those of the control group （

P

<

0.05）. During the follow-up，the evaluation indexes in the treatment group increased with time，and the corresponding growth was higher than that in the control group. There were no significant adverse reactions in both groups，and the difference was not statistically significant.

Conclusion

2

JSXT in the treatment of patients with peripheral neuropathy is superior to the control in terms of clinical symptoms，relevant scores， and electrophysiological results，with definite clinical efficacy. It is proved safe and reliable and can effectively and quickly enhance peripheral neurological function，improve the quality of life，and alleviate the negative emotions of patients. Therefore，JSXT possesses a good clinical therapeutic efficacy on patients with peripheral neuropathy and is expected to provide a new treatment method for patients with peripheral neuropathy，which is worthy of further clinical promotion.